Clinical Trials

We have both prevention and symptomatic trials. Our current prevention trial is listed at the top, followed by our symptomatic trials.

This research study (also known as a clinical trial) is of an investigational drug called gantenerumab. If you have Alzheimer’s disease (AD) or may have early symptoms of AD, you may be eligible for this study. AD is a slow progressive disease of the brain that affects memory and other normal brain functions. The brains of individuals with AD have an abundance of plaques and tangles. Plaques are deposits of a protein called amyloid; tangles are twisted fibers of another protein called tau.

Are you caring for a family member who has Alzheimer’s disease? Does your family member have symptoms of aggression or agitation or resist care?

You and your family member may be eligible for a research study evaluating low dose lithium treatment at McLean Hospital in Belmont, MA. Patients with Alzheimer’s disease are eligible. Participants will meet with a geriatric psychiatrist every two weeks for the duration of the twelve-week study.

Contact Hannah Heintz at 617.855.3225 or hheintz@partners.org for more information.

Have you been diagnosed wit bipolar disorder? Are you currently depressed? Are you over 50 years old? We are investigating the effects of Low Field Magnetic Stimulation (LFMS) on Bipolar Depression in Older Adults. Participating in this study involves clinical screening, two 2-hour sessions which include fMRI imaging and LFMS, and two follow up phone calls.

Participants may be compensated up to $200.

Contact Hannah Heintz at 617.855.3225 or hheintz@partners.org for information.

The Music, Imaging, and Neural Dynamics (MIND) Laboratory is seeking older adults with Mild Cognitive Impairment (MCI) to participate in a research study on how music intervention affects the brain and gene expression. All studies will take place at the Northeastern Interdisciplinary Science and Engineering Complex. Participants must be above 50 years old, have normal hearing, and pass pre-screening to take part in the study. Eligible participants will complete surveys, listening and cognitive tasks, MRI scanning of their brain, and blood draws.

Our study uses repetitive non-invasive transcranial magnetic stimulation to target areas of the brain that control memory and language in patients with amnestic Mild Cognitive Impairment or Primary Progressive Aphasia to improve their memory or language performance.

This study is focused on determining the effects of methylphenidate (also known as Ritalin) on the cognition, behavioral symptoms, and daily activities of people with Alzheimer’s Disease (AD) and other dementias using traditional office-based assessments as well as daily brain training games and Fitbit activity tracking.

Have you been diagnosed with early or mild Alzheimer’s disease, and between the ages of 50 to 100? Would you like to try non-invasive therapy?

This research study is using an experimental medication called RO7105705. This therapy is being tested for its ability to breakdown neurofibrillary tangles caused by tau protein. If you have moderate Alzheimer’s disease (AD), you may be eligible for this study.

Are you diagnosed with dementia with Lewy Body? Our research center is interested in using Neflamapimod can increase the cognitive function of individuals with this disease.

If you have been diagnosed with Mild Cognitive Impairment (MCI) or early onset Alzheimer’s disease, please consider our study. An FDA-approved antiretroviral HIV medication called Efavirenz will be given to participants to investigate if it can reduce cholesterol in the brain and alter the progression of Alzheimer’s disease.

Pages